A Phase 3 interventional study of MYL-1701P, a proposed biosimilar to Eylea in Diabetic Macular Edema, sponsored by Mylan Pharmaceuticals Inc. Completed at 15 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Mylan Pharmaceuticals Inc (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Macular Edema with a site in India — none open to participants now, 1 under way, none of them phase 3. Macular Edema · India.
Among the 26 studies in Macular Edema with a site in India, this one is the 22nd largest by enrollment, is one of 2 that started in 2020, is one of 12 in phase 3, and was the 19th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 26 studies in Macular Edema with a site in India is open now. The open studies under Macular Edema, anywhere →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 14 · Phase 4 6
First in 2003; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 197 across the 26 interventional studies. Of the 23 that completed or were terminated, 13 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mylan Pharmaceuticals Inc, one of the names counted as Viatris Inc.. Under that name alone:
Mylan Pharmaceuticals Inc is the lead sponsor of 160 studies on the registry; 1 is open to participants now.
Viatris Inc. has 2 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies in Macular Edema with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Macular Edema with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
Diabetic retinopathy is an important cause of blindness worldwide. The International Diabetes Federation estimates that 285 million people worldwide have diabetes mellitus and approximately 7% of these individuals are affected by diabetic macular edema.
EYLEA® (aflibercept) injection, an anti-Vascular Endothelial Growth Factor (VEGF) agent, has been approved by the FDA and EMA for the treatment of Diabetic Macular Edema (DME).
Mylan Inc. and Momenta Pharmaceuticals, Inc. are developing MYL-1701P, a proposed biosimilar to Eylea.
MYL-1701P-3001 (NCT03610646) study was designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of MYL-1701P in the treatment of subjects with Diabetic Macular Edema (DME). Eligible subjects from MYL-1701P-3001 (NCT03610646) study will be enrolled in the AFIL-IJZ-3002 study. All enrolled subjects will receive three doses of MYL-1701P every eight weeks. Subjects will attend the clinic visits for safety and efficacy assessments including Best Corrected Visual Acuity (BCVA), Spectral domain- Optical Coherence Tomography (SD-OCT), complete ophthalmological examinations during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, subject must be:
Exclusion Criteria:
Subjects will be excluded if any of the following conditions are met in the study eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label, single arm study
Biological: MYL-1701P, a proposed biosimilar to Eylea
MYL-1701P- 3 doses each of 2 mg at 8 weeks interval
Incidence of Treatment Emergent Adverse Events (TEAEs).
Incidence of treatment-emergent adverse events was defined as the number and percentage of participants experiencing at least one TEAE during the study period. Incidence is reported as categorical participant counts rather than person-time-based rates due to the fixed study duration.
Time frame: Week 20
Change From Baseline in BCVA at Week 8
Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)
Time frame: Week 8
Change From Baseline in CRT at Week 8
Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)
Time frame: Weeks 8
Change From Baseline in BCVA at Week 16
Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)
Time frame: Week 16
Change From Baseline in BCVA at Week 20
Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)
Time frame: Week 20
Change From Baseline in CRT at Week 16
Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)
Time frame: Week 16
Change From Baseline in CRT at Week 20
Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)
Time frame: Week 20
Parent study (MYL-1701P-3001) was designed to demonstrate the clinical similarity of MYL 1701P and Eylea regarding efficacy, safety, pharmacokinetics, and immunogenicity in the treatment of subjects with DME. AFIL-IJZ-3002 study was designed and conducted by Mylan to further evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of subjects who successfully completed the parent study MYL-1701P-3001.
| Milestone | Single, Test Arm |
|---|---|
| Started | 52 |
| Completed | 46 |
| Not completed | 6 |
Incidence of treatment-emergent adverse events was defined as the number and percentage of participants experiencing at least one TEAE during the study period. Incidence is reported as categorical participant counts rather than person-time-based rates due to the fixed study duration.
| Participants | Single, Test Arm |
|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs). | 16 |
Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)
| Letters | Single, Test Arm |
|---|---|
| Change From Baseline in BCVA at Week 8 | 1.4 ± 2.88 |
Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)
| Microns | Single, Test Arm |
|---|---|
| Change From Baseline in CRT at Week 8 | -23.8 ± 102.42 |
Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)
| Letters | Single, Test Arm |
|---|---|
| Change From Baseline in BCVA at Week 16 | 1.4 ± 3.74 |
Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)
| Letters | Single, Test Arm |
|---|---|
| Change From Baseline in BCVA at Week 20 | 1.5 ± 3.80 |
Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)
| Microns | Single, Test Arm |
|---|---|
| Change From Baseline in CRT at Week 16 | -6.2 ± 130.55 |
Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)
| Microns | Single, Test Arm |
|---|---|
| Change From Baseline in CRT at Week 20 | -14.8 ± 89.71 |
Collected over The total study duration was 24 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single, Test Arm | 0/52 (0%) | 1/52 (1.9%) | 16/52 (30.8%) |
| Event | Single, Test Arm |
|---|---|
| Cerebral InfarctionNervous system disorders | 1/52 |
| Event | Single, Test Arm |
|---|---|
| Glycosylated haemoglobin increasedInvestigations | 4/52 |
| Eye painEye disorders | 3/52 |
| CataractEye disorders | 2/52 |
| PyrexiaGeneral disorders | 2/52 |
| Bundle branch block leftCardiac disorders | 1/52 |
| Cataract nuclearEye disorders | 1/52 |
| Diabetic retinal oedemaEye disorders | 1/52 |
| Eye irritationEye disorders | 1/52 |
| Ocular hyperaemiaEye disorders | 1/52 |
| Posterior capsule opacificationEye disorders | 1/52 |
All enrolled population
| Age, Categorical(Participants) | Single, Test Arm |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 41 |
| >=65 years | 11 |
| Sex: Female, Male(Participants) | Single, Test Arm |
|---|---|
| Female | 16 |
| Male | 36 |
| Ethnicity (NIH/OMB)(Participants) | Single, Test Arm |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 52 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Single, Test Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 52 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Single, Test Arm |
|---|---|
| India | 52 |
| Best Corrected Visual Acuity(Letters) | Single, Test Arm |
|---|---|
| Mean | 70.6 ± 14.1 |
| Corneal Retinal Thickness(micrometers) | Single, Test Arm |
|---|---|
| Mean | 318.7 ± 132.85 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Apr 2022, 16 months.
Results were first posted in Aug 2026, 4 years 3 months after primary completion. A results delay was requested in Aug 2022.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 16 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.